Dr Matteo Lambertini presents the findings from the PREFER study, a multicenter prospective cohort study on oncofertility counseling and fertility preservation in premenopausal women with early breast cancer.

The study found that a majority of patients accepted gonadotropin-releasing hormone agonist during chemotherapy, with 25% of patients under 40 opting for cryopreservation.

The study also showed no detrimental effect of controlled ovarian stimulation for oocyte cryopreservation on disease-free survival or overall survival.